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ABSTRACT
Background: NSAIDs have been found to induce gastrointestinal tract damage. 
Recently, it has been suggested that this might be mediated by lipid peroxidation.
Objective: The aim of this study was to assess the potential protective effects 
of β-glucan against acetylsalicylic acid (ASA)–induced gastric damage by means of its 
antioxidant capacity in an experimental rat model.
Methods: Thirty-two male Wistar albino rats (200–250 g) were randomized 
into 4 groups consisting of 8 rats each. The β-glucan group received 50 mg/kg 
β-glucan once a day for 10 days and 30 minutes before anesthesia. The ASA group 
received saline once a day for 10 days and 300 mg/kg (20 mg/mL) ASA as a single 
dose, 4 hours before anesthesia. The ASA+β-glucan group was administered 50 mg/kg 
β-glucan once a day for 10 days and 30 minutes before anesthesia. Additionally, 
300 mg/kg (20 mg/mL) ASA was administered as a single dose, 4 hours before anes-
thesia. The control group received saline once a day for 10 days and 30 minutes before 
anesthesia. All medications were administered by intragastric gavage. The stomach 
from each rat was dissected and divided into 2 parts for histologic and biochemical 
analysis. Gastric tissue malondialdehyde (MDA), nitric oxide (NO) levels, catalase 
(CAT), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) activities 
were determined for oxidative parameter analysis.
Results: The gastroprotective and antioxidant effects of β-glucan appeared to 
attenuate the ASA-induced gastric tissue damage. Compared with the control group, 
MDA and NO levels and CAT and GSH-Px activities were significantly increased 
in the stomachs of ASA-treated rats (MDA, 4.12 [0.44] to 13.41 [1.05] μmol/L; NO, 
8.04 [7.25–9.10] vs 30.35 [22.34–37.95] μmol/g protein; CAT, 0.050 [0.004] 
to 0.083 [0.003] k/g protein; GSH-Px, 0.57 [0.42–0.66] to 1.55 [1.19–1.76] U/L; 
all, P < 0.001), whereas SOD activity was significantly decreased in the same group 
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(291 [29] to 124 [6] U/mL; P < 0.001). In the ASA+β-glucan group, MDA and NO 
levels and CAT and GSH-Px activities were found to be significantly lower, while 
SOD activity was found to be significantly higher, in comparison with the ASA-
treated group (all, P < 0.001).
Conclusion: β-Glucan appeared to attenuate the gastric damage caused by 
ASA in these rats. (Curr Ther Res Clin Exp. 2010;71:369–383) © 2010 Elsevier HS 
Journals, Inc.
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INTRODUCTION
An imbalance between the offensive factors such as acid and pepsin secretion and 
defensive factors namely mucin secretion, cellular shedding and proliferation and 
prostaglandin (PG) synthesis, has been suggested to play a role in the pathogenesis of 
gastrointestinal ulcers.1
NSAIDs such as acetylsalicylic acid (ASA) are widely used antiinflammatory and 
analgesic agents. Unfortunately, they have been found to result in gastrointestinal 
ulcers through a number of mechanisms which still remain to be elucidated.2 Sup-
pressed PG synthesis due to inhibition of cyclooxygenase, direct irritant action dis-
turbing the mucosal permeability, and neutrophil recruitment and activation have 
been suggested to be responsible for gastric ulcers. Recently, lipid peroxidation (LPO) 
mediated by reactive oxygen species (ROS) has been implicated in playing a crucial 
role in ulcer-related oxidative damage.3–5
Endogenous antioxidant enzymes in tissues, namely, glutathione peroxidase (GSH-Px), 
superoxide dismutase (SOD), and catalase (CAT) act to scavenge ROS in order to 
prevent LPO-mediated tissue damage.1 Impaired balance between those ROS and 
endogenous antioxidants may be responsible for some clinical situations such as sepsis, 
ischemia reperfusion injury, and gastrointestinal ulcers. A variety of compounds may 
prove beneficial for preventing gastric ulcers through scavenging highly destructive 
ROS and inhibiting LPO.1,6
β-Glucan is a complex carbohydrate derived from broken cell walls of yeast, fungi, 
and cereals by a purification procedure that yields β-glucan polymer as a soluble form.7,8 
It has been found to be associated with decreasing unhealthy amounts of cholesterol and 
boosting the immune system.9,10 It acts on macrophages, B lymphocytes, supressor 
T cells, and natural killer cells. It enhances neutrophil mobilization and migration by 
binding to the receptors located on monocytes.11 It has also been found to be an effica-
cious antioxidant and free-radical scavenger.12,13 It has been reported to be a critical 
potentiator for mucosal immunity in the digestive tract.14 Therefore, β-glucan might be 
beneficial for a variety of clinical situations through its complex interactions with pro- 
inflammatory cytokines and endogenous antioxidants.15,16
The present study assessed the potential protective effects of β-glucan against experi-
mentally induced gastric ulcers in rats through its free radical scavenger action based on 
gastric tissue malondialdehyde (MDA) and nitric oxide (NO) levels, and CAT, GSH-Px, 
and SOD activities.
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MATERIALS AND METHODS
Experimental Design
The experiments were carried out on a total of 32 male Wistar albino rats weighing 
between 200–250 g. All rats were maintained under the same conditions before the 
surgical procedure. The animals were housed at 22°C ± 2°C and 40% to 45% relative 
humidity in wire bottom colony cages (4 rats/cage) with a 12-hour light/dark cycle 
(7:00 am–7:00 pm) and fed standard rat chow. Food was withdrawn for 18 hours before 
the experiments, but access to water was ad libitum. Care was taken to prevent co-
prophagy. The experiments were in compliance with the Principles of Laboratory 
Animal Care formulated by the National Institutes of Health.17 The study protocol 
was approved by the committee for the ethical care and use of laboratory animals of 
Mustafa Kemal University, School of Medicine.
Animal Treatment
The animals were randomized into 4 groups consisting of 8 rats each according to 
body weight (each group had the same relative mean weight). The β-glucan–treated 
group was treated with 50 mg/kg β-glucan* in microparticulate form (suspended 
with saline) once a day for 10 days and 30 minutes before anesthesia. The ASA-treated 
group received oral saline once a day for 10 days and 30 minutes before anesthesia and 
was administered a single dose of ASA 300 mg/kg (20 mg/mL; Bayer, Istanbul, Turkey) 
4 hours before anesthesia. The ASA+β-glucan–treated group received 50 mg/kg 
β-glucan once a day for 10 days and 30 minutes before anesthesia and a single dose of 
ASA 300 mg/kg (20 mg/mL) 4 hours before anesthesia. The control group received 
oral saline once a day for 10 days and 30 minutes before anesthesia.
All the medications were administered orally by gavage through an intragastric 
tube. In each of the groups, fluids were administered at 6 mL/kg with medication.
Anesthesia of the animals was achieved through intramuscular injection of a mix-
ture involving ketamine (80 mg kg–1) (Ketalar, Pfizer Inc, Istanbul, Turkey) and 
xylazine hydrochloride (1.5 mg/kg) (Rompun, Bayer). Laparotomy was conducted and 
pylorus ligation was performed with no damage to the blood supply, followed by the 
esophageal clamping. The stomach was dissected and the rats were euthanized by 
cervical dislocation. The stomachs were cut open along the greater curvature and the 
mucosae were rinsed with saline solution to remove the blood. Photographs of both 
forestomach and the glandular parts demonstrating the macroscopic appearance of the 
stomach were taken. The stomachs were divided into 2 parts for histologic and bio-
chemical studies.
There were 2 primary outcome measures. The first was the demonstration of LPO, 
oxidative injury induced by ASA treatment by means of measuring MDA, NO levels, 
CAT, SOD, and GSH-Px activities in gastric tissue. The second was the determination 
of potential preventative effects of β-glucan against ASA-induced gastric injury 
through examination of the alterations in oxidative injury parameters following the 
*Trademark: Immunex® (Mustafa Nevzat Company, Istanbul, Turkey).
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use of β-glucan. Secondary outcome measures were the histologic changes in gastric 
tissue following ASA exposure and the potential protective role of β-glucan in the case 
of ASA-induced gastric damage with respect to histologic consequences.
Histologic Analysis
The freshly excised stomachs were examined macroscopically for hemorrhagic lesions 
developing in the glandular mucosa. For histologic examination, stomach tissue speci-
mens were fixed in 10% formalin solution. Following embedding in paraffin, sections 
from blocks (4–5 mm) were stained with hematoxylin and eosin and examined with a 
light microscope (BH-2, Olympus America Inc., Melville, New York).3,18
Ulcer Scoring
Ulcer scoring was made by summing 2 scores. First, a macroscopic score was ob-
tained by adding the total number of ulcers per stomach and the total severity of ul-
cers per stomach in each group. For macroscopic evaluation, all 8 samples in each 
group were observed. The sum of the total macroscopy score in each group was then 
divided by the number of rats in that group and a mean ulcer index (MUI) 1 was 
calculated (Table I). Secondly, at least 3 sections from each specimen were randomly 
selected and evaluated microscopically and scored (Table II). Points from all 3 sec-
tions in each group were summed and a microscopic score was obtained for each rat. 
The scores for each rat were then summed and divided by the number of rats to obtain 
the MUI 2 score. Finally, MUI 1 and MUI 2 were summed to derive a total ulcer score 
(TUS). Macroscopic and microscopic analysis was performed by an investigator who 
was not involved in the experimental procedures.
Biochemical Analysis
Oxidative Parameters
The gastric tissue samples were stored at –30°C until assayed for gastric tissue 
MDA, NO levels, CAT, SOD, and GSH-Px activities.
Stomach tissues were homogenized (for 2 minutes at 5000 rpm) in 4 volumes of 
ice-cold Tris-HCl buffer (50 mmol, pH 7.4) using a glass Teflon homogenizer (T10 
Basic Ultra Turrax, IKA Werke GmbH & Co. KG, Staufen, Germany). MDA, NO, 
Table I. Macroscopic scoring of gastric lesions.
 Number of Macroscopic 
Lesion Type Lesions Score
Linear hemorrhagic >5 5
 3–5 4
 1–3 3
Dot-like or patchy >3 2
 1–3 1
None – 0
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and protein levels were measured at the homogenate level. Then, the homogenate was 
centrifuged at 5000g for 60 minutes to remove debris. Supernatant fluid was collected 
and CAT and GSH-Px activities, as well as protein concentration, were measured. The 
supernatant solutions were used for the assay. The supernatant solutions were mixed 
with an equal volume of an ethanol/chloroform mixture (5/3, v/v). After centrifuga-
tion at 5000g for 30 minutes, the clear upper layer (the ethanol phase) was collected 
and used in the analysis of SOD activity and protein assays. All preparation procedures 
were carried out at 4°C.
Determination of MDA Levels
The thiobarbituric acid reactive substance level was determined by a method based 
on the reaction with TBA at 90°C to 100°C.19 In the TBA test reaction, MDA or 
MDA-like substances (ie, the byproduct of lipid peroxidation process of the poly- 
unsaturated fatty acids) and TBA react together for production of a pink pigment 
having an absorption maximum at 532 nm. The reaction was performed at pH 2 to 
3 at 90°C for 15 minutes. The sample was mixed with 2 volumes of cold 10% 
(w/v) trichloroacetic acid to precipitate protein. The precipitate was pelleted by cen-
trifugation and an aliquot of the supernatant was reacted with an equal volume of 
0.67% (w/v) TBA in a boiling water bath for 10 minutes. After cooling, the absor-
bance was read at 532 nm (UV-1800, Shimadzu Corp., Tokyo, Japan). The results 
were expressed as nmol/g protein.
Determination of NO Levels
Because NO is a very labile molecule, its direct measurement in biological samples 
is difficult. In aqueous solution, NO reacts with molecular oxygen and accumulates 
in the plasma as nitrite (NO2¯) and nitrate (NO3¯) ions. Therefore, the stable oxida- 
tion end products of NO, NO2¯, and NO3¯ can be readily measured in biological 
fluids and have been used in vitro and in vivo as indicators of NO production. Tissue 
nitrite plus nitrate concentrations as an index of plasma NO levels were determined 
by the method described previously.20 Quantification of nitrite and nitrate was based 
on the Griess reaction, in which a chromophore with a strong absorbance at 540 nm 
is formed by reaction of nitrite with a mixture of naphthylethylenediamine and sulfa-
nilamide. The absorbance was measured in a spectrophotometer (UV-1800, Shimadzu 
Corp.) to assess the nitrite concentration. For nitrate detection, a second sample was 
Table II. Microscopic scoring of gastric lesions.
Lesion Microscopic Score
Significant erosion 3
Swollen gastric glands with hemorrhagic  
areas and exfoliation of epithelial cells 2
Two or fewer lesions with significant erosion 1
None 0
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treated with copperized cadmium in glycine buffer at pH 9.7 to reduce nitrate to 
nitrite, the concentration of which represented the total nitrite plus nitrate. A stan-
dard curve was established with a set of serial dilutions (10−8–10−3 mol/L) of sodium 
nitrite. Results were expressed as μmoL/g protein.
Determination of CAT Activity
CAT (EC 1.11.1.6) activity was measured according to the method of Aebi et al.21 
The principle of the assay is based on the determination of the rate constant k (dimen-
sion: s–1, k) of hydrogen peroxide (H2O2) decomposition. By measuring the absor-
bance changes per minute, the rate constant of the enzyme was determined. Activities 
were expressed as k/mg protein.
Determination of GSH-Px Activity
GSH-Px (EC 1.6.4.2) activity was measured using the method of Paglia and Valen-
tine.22 The enzymatic reaction was initiated by the addition of H2O2 to the reaction 
mixture containing glomerulus-stimulating hormone, nicotinamide adenine dinucleo- 
tide phosphate, and glutathione reductase. The change in the absorbance at 340 nm was 
monitored by a spectrophotometer. Activity was reported in U/g protein.
Determination of SOD Activity
The principle of the total SOD (EC 1.15.1.1) activity method is based, briefly, on the 
inhibition of nitroblue tetrazolium (NBT) reduction by O2¯ generated by a xanthine/
xanthine oxidase system.23 Activity was assessed in the ethanol phase of the serum after 
1.0 mL ethanol/chloroform mixture (5/3, v/v) was added to the same volume of serum 
and centrifuged. One unit of SOD was defined as the enzyme amount causing 50% 
inhibition in the NBT reduction rate. Activity was expressed as U/g protein.
Statistical Analysis
Data were analyzed by using SPSS for Windows version 15.0 (SPSS Inc., Chicago, 
Illinois). Distribution of the groups was analyzed with the 1-sample Kolmogrov-
Smirnov test. Groups showed normal distribution for the level of MDA and the ac-
tivities of CAT and SOD so that parametric statistical methods were used to analyze 
the data. A 1-way ANOVA test was performed and post hoc multiple comparisons 
were made using least squares differences. Results are presented as mean (SEM).
The distribution was not normal for NO and GSH-Px levels in groups. The level 
of NO and the activity of GSH-Px were assessed between groups using the Kruskal-
Wallis test. The Mann-Whitney U test was used for the difference between 2 groups. 
The results were presented as median and 25th and 75th interquartile range. P < 0.05 
was considered to be statistically significant for all data.
RESULTS
Histologic Analysis
In the macroscopic analysis, no damage was noted in the forestomachs of rats in the 
β-glucan, ASA+β-glucan, and control groups. On the other hand, all ASA group 
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members showed patchy and dot-like pale lesions. When compared with the glandu-
lar regions, lesions were fewer, and there were no linear hemorrhagic lesions.
In the glandular stomach, the most evident finding was linear hemorrhagic lesions 
in the ASA group (Figure, B). Eight rats in this group had multiple linear lesions and 
1 showed dot-like lesions. Patchy pale lesions accompanied hemorrhagic lesions in all 
samples.
In the ASA+β-glucan group, glandular region showed few dot-like and pale lesions 
with no linear hemorrhagic lesions compared with the ASA group (Figure, C). Both 
glandular mucosa and forestomach regions in the ASA+β-glucan group were no dif-
ferent than those of the control (Figure, A) and β-glucan groups.
In the microscopic examination, the most striking changes occurred in the ASA 
group. Mucosa was disrupted with erosions. Lesions were extending deep into the 
mucosa but did not penetrate the muscularis mucosa (Figure, D). Exfoliation of 
A CB
D E F
Figure.  Macroscopic and microscopic examination of stomachs: (A) control rat showing 
normal forestomach and glandular stomach; (B) linear hemorrhagic lesions (Æ) in 
glandular stomach of the acetylsalicylic acid (ASA) group; (C) few dot-like and 
pale lesions (Æ) with no linear hemorrhagic ulcerations in the ASA+β-glucan 
group; (D) hematoxylin and eosin staining of stomach tissue in rats administered 
ASA showing the severity of the erosion (*). Note that muscularis mucosa is in-
tact (Æ) (magnification ×40); (E) hematoxylin and eosin staining of stomach 
tissue of the ASA group showing hemorrhagic areas (Æ) and impaired gastric 
glands (*) (magnification ×200); and (F) swollen gastric glands (*) and hemor-
rhagic areas (Æ) in the ASA+β-glucan group (magnification ×400).
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gastric epithelial cells, disruption in the glandular structure, and hemorrhagic lesions 
were observed (Figure, E).
Pretreatment with β-glucan was associated with fewer gastric lesions when com-
pared with the ASA group. No erosions were noted. However, a few changes such as 
swollen gastric glands and hemorrhagic areas were observed (Figure, F).
In statistical analysis, histologic findings as formulated as TUS scores were found 
to be 0.37 (0.26), 7.12 (0.29), 2.87 (0.35), and 0.62 (0.32) in the β-glucan, ASA, 
ASA+β-glucan, and control groups, respectively. TUS scores significantly differed 
among control and ASA, ASA and ASA+β-glucan, and control and ASA+β-glucan 
groups (all, P < 0.001) (Table III).
Biochemical Analysis
MDA levels and CAT and SOD enzyme activities are shown in Table IV. MDA 
levels and CAT activity were found to be significantly increased in the stomachs of 
rats treated with ASA, whereas SOD activity was found to be significantly decreased 
in the same group in comparison with the control group (MDA, 4.12 [0.44] to 13.41 
[1.05]; CAT, 0.050 [0.004] to 0.083 [0.003]; SOD, 291 [29] to 124 [6]; all, P < 
0.001). In the group that received β-glucan alone, CAT activity was significantly 
decreased when compared with the control group (0.050 [0.004] to 0.036 [0.003]; 
P = 0.02). MDA levels and CAT activity in the ASA+β-glucan group were found 
to be significantly lower when compared with the ASA-treated group (13.41 [1.05] 
vs 5.24 [0.47], 0.083 [0.003] vs 0.044 [0.004]; both, P < 0.001). SOD activity in the 
ASA+β-glucan group was found to be significantly higher in comparison with the 
ASA-treated group (124 [6] vs 278 [14]; P < 0.001). As shown in Table V, ASA was 
associated with significantly increased median (interquartile range) levels of NO in 
comparison with the control group (8.04 [7.25–9.10] vs 30.35 [22.34–37.95]; P < 
0.001) (Table V). NO was found to be significantly lower in the ASA+β-glucan 
group (8.52 [7.60–9.84]; P < 0.001) when compared with the ASA-treated group. 
ASA treatment alone was associated with a significant rise in GSH-Px activity in 
comparison with the control group (0.57 [0.42–0.66] to 1.55 [1.19–1.76]; P < 
0.001) (Table V). GSH-Px activity was found to be significantly lower in the ASA+ 
β-glucan group (0.58 [0.51–0.64]; P < 0.001) when compared with the ASA-treated 
group.
Table III. Total ulcer score (TUS) comparison between groups. Data are mean (SD). 
 β-Glucan ASA ASA+β-Glucan Control 
Variable (n = 8) (n = 8) (n = 8) (n = 8) P*
TUS 0.37 (0.26) 7.12 (0.29)† 2.87 (0.35)†‡ 0.62 (0.32) P < 0.001 
     (F = 101.79)
ASA = acetylsalicylic acid.
 * One-way ANOVA.
 † P < 0.001 versus the control group (least squares difference).
 ‡ P < 0.001 versus the ASA group (least squares difference).
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DISCUSSION
ASA-induced gastric mucosal injury has been recently suggested to occur via LPO 
associated with ROS.3,24 Membrane peroxidation mediated by ROS leads to altered 
membrane permeability and protein degradation, followed by cell lysis. MDA, the 
product of LPO, has been adopted as a measure of free radical production and, there-
fore, an “index of LPO.” SOD and GSH-Px activities in tissues are other parameters 
that may be used to monitor the extent of LPO.9,25
A variety of natural and synthetic antioxidant compounds, namely, melatonin,3 
Asparagus racemosus,24 rebamipide,2 and fish oil,1 have been found to inhibit oxidative 
damage by enhancing the activity of endogenous antioxidant enzymes and scavenging 
the highly destructive free radical species and, therefore, restoring the balance in favor 
of antioxidant enzymes counteracting the free radicals.9,24 Antiulcerogenic activity 
Table IV.  The levels of malondialdehyde (MDA) and the activities of catalase (CAT) and 
superoxide dismutase (SOD) in groups. Data are mean (SEM).
Parameter
β-Glucan 
(n = 8)
ASA 
(n = 8)
ASA+ β-Glucan 
(n = 8)
Control 
(n = 8) P*
MDA, nmoL/g 
protein
4.45 (0.57) 13.41 (1.05)† 5.24 (0.47)‡ 4.12 (0.44) P < 0.001 
(F = 41.75)
CAT, k/mg 
protein
0.036 
(0.003)§
0.083 
(0.003)†
0.044 
(0.004)‡
0.050 
(0.004)
P < 0.001 
(F = 28.26)
SOD, U/g  
protein
302 (20) 124 (6)† 278 (14)‡ 291 (29) P < 0.001 
(F = 17.66)
ASA = acetylsalicylic acid.
 * One-way ANOVA.
 † P < 0.001 versus the control group (least squares difference).
 ‡ P < 0.001 versus the ASA group (least squares difference).
 § P < 0.02 versus the control group (least squares difference).
Table V.  Nitric oxide (NO) levels and glutathione peroxidase (GSH-Px) activities in the 
study groups. Data are median (25th–75th percentile).
   ASA+ 
 β-Glucan ASA β-Glucan Control 
Parameter (n = 8) (n = 8) (n = 8) (n = 8)
NO, μmol/g protein 7.55 30.35 8.52 8.04 
 (5.85–9.24) (22.34–37.95)* (7.60–9.84)† (7.25–9.10)
GSH-Px, U/g protein 0.44 1.55 0.58 0.57 
 (0.31–0.60) (1.19–1.76)* (0.51–0.64)† (0.42–0.66)
ASA = acetylsalicylic acid.
 * P < 0.001 versus the control group.
 † P < 0.001 versus the ASA group.
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of the aforementioned agents might be attributed to the antioxidant action of those 
molecules.
β-Glucan has been found to inhibit tumor development,26 enhance defense against 
infections,8,27 activate macrophages, induce production and release of cytokines, NO, 
and arachidonic acid metabolites, increase hematopoeisis,28–30 exert radioprotective 
effects, be effective against thermal trauma, improve wound healing,18,31 and lower 
serum cholesterol levels.18 It has been reported to be an effective antioxidant and free- 
radical scavenger, which are among the several mechanisms proposed for the protec-
tive effects of β-glucan in all those processes.9,18,25
Based on the free-radical scavenging activity and potential protective effects of 
β-glucan in different pathologic processes where LPO plays a crucial role, we investi-
gated the impact of β-glucan on acidified gastric mucosa by ASA use and potential 
antiulcerogenic activity of the drug.
In the present study, we observed that ASA administration was associated with 
significant changes in gastric tissue both macroscopically and microscopically. The 
most striking findings were linear hemorrhagic lesions, erosions limited to the mus-
cularis mucosa, and impaired gastric glands. Similar histologic findings were also 
reported by Sener-Muratoglu et al,3 Sairam et al,24 and Choi et al.32 Another impor-
tant observation was that β-glucan was associated with significantly improved gastric 
glandular structure. This might be due to the gastroprotective and antioxidant effects 
of β-glucan in addition to its capacity to modulate the mucosal immunity of the in-
testinal tract.14 We developed our own ulcer scoring method that combined both 
macroscopic and microscopic findings. In previous studies, different scoring methods 
have been used. Millar et al33 performed both microscopic and macroscopic scorings 
and evaluated them separately. Szabo et al34 used a macroscopic index and Sarkar and 
Buha35 measured mucosal thickness to obtain a microscopic score. We preferred to 
combine both findings with an adaptation based on the literature. As supported by 
the literature, we gave top scores to evident erosions and ulcerations and rated other 
findings. Our results supported this new scoring system with significant values be-
tween the ASA and β-glucan groups.
Regarding the analysis of oxidative-damage parameters indicating LPO in this 
study, gastric tissue levels of MDA, NO levels, and CAT and GSH-Px activities were 
found to be significantly increased in ASA-induced gastric damage in rats; however, 
SOD activity was found to be significantly decreased in the same group. Subsequently, 
β-glucan pretreatment in ASA-induced gastric ulcers (ASA+β-glucan group) was 
found to depress LPO as it resulted in a higher SOD activity and lower MDA levels 
in comparison with the group administered only ASA, suggesting the protective ef-
fect of β-glucan against oxidative tissue damage. Previous studies have suggested 
similar findings. Local or systemic use of β-glucan was found to inhibit MDA eleva-
tions in cases of sepsis- or burn-induced oxidative tissue damage.8,18 Toklu et al,18 
who investigated the putative protective effect of local or systemic β-glucan treatment 
on burn-induced remote organ injury in rats, found that severe skin-scald injury re-
sulted in decreased glomerulus-stimulating hormone levels of the liver and intestinal 
tissues (P < 0.01 and P < 0.001). MDA levels were significantly increased at 6 and 
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48 hours post burn (P < 0.01 and P < 0.001). Local and systemic β-glucan treat- 
ment was associated with reducing MDA and increasing glomerulus stimulating 
hormone levels back to control levels. The same investigators later reported an inhibi-
tory effect of β-glucan with respect to MDA production that implied a reduction in 
LPO-mediated cellular injury and protection of the liver against acetaminophen- 
induced oxidative damage in mice.36 Sener et al37 investigated oxidative organ injury 
following a single dose of methotrexate injection in rats. Methotrexate was associated 
with a significant decrease in glomerulus stimulating hormone levels while MDA 
levels, LPO activity, and collagen content were significantly increased in the ileum, 
liver, and renal tissues. β-Glucan use following methotrexate-induced oxidative organ 
injury was also found to eliminate the depletion of GSH-Px and inhibit the increases 
in MDA levels, LPO activity, and collagen content in addition to attenuation of tissue 
damage observed in histologic analysis. The findings of Senoglu et al7 are also in ac-
cordance with our data that β-glucan treatment was associated with significantly re-
versing the diminished SOD activity and high MDA levels in hepatic tissue of a rat 
model where sepsis was induced by cecal ligation and puncture. Another experimental 
study of ischemia reperfusion injury in rabbits supported the conclusions of the previ-
ous studies.9 β-Glucan administration was associated with decreased MDA and NO 
levels, whereas increased SOD and GSH-Px activities suggested that antioxidant 
medication might help lower limb ischemia reperfusion injury. However, Kayali et 
al25 reported no effect of β-glucan on SOD and MDA activities, and GSH-Px levels 
were decreased to preinjury levels (P = 0.002) in case of spinal cord injury in an ex-
perimental rat model.
In the present study, ASA was associated with significantly increased levels of NO 
in gastric tissue. ASA has been found to induce NO release from vascular endotheli-
um.38 It was suggested that ASA directly stimulates the activity of endothelial NO 
synthase without affecting the expression of endothelial NO synthase (NOS).39 Inducible 
NOS (iNOS) expression and iNOS-derived NO synthesis were observed in leucocytes 
of the mesentery of ASA-treated rats.40 However, NO functions as a smooth muscle- 
relaxing agent and counteracts the reduction in gastric blood flow caused by inhibi- 
tors of prostaglandin synthesis. Therefore, stimulation of NO formation through ASA 
might help to reduce gastric injury or irritation.39 Some researchers have reported 
that β-glucans stimulate the production of NO,41 whereas other researchers have 
found that β-glucan has no effect on the production of NO in vivo or in vitro.42 
β-Glucan administration alone did not induce any NO production in the present 
study, but β-glucan was associated with decreased ASA-induced NO production. 
Most likely, β-glucan does not affect the basal release of NO, but reduces the increased 
NO production. Indeed, Young et al43 reported that lipopolysaccharide-induced NO 
production by alveolar macrophage was decreased by in vivo pretreatment with zymo-
san (1→3–β-glucan).
Comparable to the present study, β-glucan decreased GSH-Px levels to the prein-
jury levels in spinal cord–injured rats and the administration of β-glucan alone did not 
change GSH-Px levels.25 Researchers have found that β-glucan inhibits CAT activity 
and dramatically increases H2O2 accumulation suspension-cultured cells of potato and 
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tobacco leaf explants.44,45 However, there are some studies that do not support our 
results. Reverberi et al46 reported that β-glucans stimulate GSH-Px, CAT, and other 
antioxidant enzyme activities.9 The literature regarding this issue appears to be con-
troversial. According to the findings of Bobek and Galbavy,47 diet containing pleuran 
(β-glucan) reduced GSH-Px activity and increased CAT activity in erythrocytes. 
Moreover, CAT levels in the liver tissue were significantly increased by β-glucan 
administration.7 β-glucan at concentrations of 42.5, 85, 170, and 340 mg × 100 mL–1 
markedly increased the activities of antioxidant enzymes such as CAT in human red 
blood cell hemolysates and in fish erythrocytes.48,49 It may be a partial explanation for 
the conflicting results: the effect of β-glucan on antioxidant enzyme activity may be 
dose-dependent. The doses of β-glucan are similar in the supporting studies related 
to GSH-Px. An explanation is more difficult for different CAT activities. The effect 
of β-glucan on CAT enzyme activity may be dose-dependent or its cellular effects may 
vary. Indeed, the effect of β-glucan on CAT activity is variable in different cell types 
in vitro.44,45,47–49 β-Glucan might directly reduce CAT activity, but indirectly reduce 
the activity of GSH-Px, because β-glucan itself scavenges free radicals.
Further parameters of oxidative injury such as myeloperoxidase activity and tissue 
collagen content (a free radical-induced fibrosis marker)3,36,37 and additional assess-
ments such as determination of gastric mucus secretion and gastric acidity1,3 and es-
timation of cellular mucin as glycoproteins1,24 are lacking in the present study. Those 
variables may be promising contributory parameters for future investigation. Based on 
its potential antioxidant capacity, β-glucan may be considered of therapeutic value for 
the prevention and/or treatment of ASA-induced gastric ulcers. Future investigation 
with rigorous scientific design is required to clarify the role of β-glucan pretreatment 
for the prevention of ASA-induced gastric damage.
CONCLUSION
β-Glucan appeared to attenuate the gastric damage caused by ASA in these rats. 
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